Skip to main content
. Author manuscript; available in PMC: 2008 Feb 23.
Published in final edited form as: Mol Cell. 2007 Feb 23;25(4):491–503. doi: 10.1016/j.molcel.2007.01.021

Figure 2.

Figure 2

PI and CaM binding domains (CBDs) overlapped in the TRPC6 C-terminus. (A) Schematic of C-terminal regions of TRPC6 (C6-C) fused to MBP. The TRP domain and CBD are indicated. The residues in TRPC6 included in the fusions are indicated. The sixth transmembrane domain is predicted to end at residue 727. (B) Relative IP6 binding to the MBP-TRPC6-C fusion proteins. The bindings were based on determination of the CPMs using [3H]IP6 (±SEMs; n≥3): C6-C, 100.0 ±23.8; fragment 1, 134.4 ±13; fragment 2, 168.3 ±5.9; fragment 3: 36.9 ±8.6; fragment 4; 30.7 ±18.6; fragment 5, 125.3 ±12.4; fragment 6: 236 ±7.4). (C) PCaM domain. Indicated in bold are the positively charged amino acids mutated. (D) Relative IP6 binding to wild-type and mutant MBP-TRPC6-C fusion proteins. The relative bindings were based on determination of the CPMs using [3H]IP6 (±SEMs; n≥3): wild-type, 100.0 ±2.6; R853Q, 36.7 ±4.4; K860Q, 85.9 ±2.8; R861Q, 76.5 ±3.2; R865Q, 97.3 ±13.7; R853Q/K860Q, 22.1 ±3.6; R853Q/R861Q, 30.3 ±3.1; K860Q/R861Q, 62.3 ±5.3; R853Q/K860Q/R861Q, 24.9 ±4.1). Asterisks indicate statistically significant differences from wild-type using the unpaired Student’s t-test, value <0.05.